In SPG11, comorbidities such as obesity, reduced mobility, and adipokine dysregulation appear integral to disease expression, with progressive motor impairment driving immobility, increased adiposity, inflammatory imbalance, and worsening metabolic stress [37]. Here, SPG11 is linked to obesity due to melanocortin 4 receptor deficiency.